Eli Lilly and Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eli Lilly and in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Eli Lilly and stock.
View analyst ratings for Eli Lilly and or view top-rated stocks.

17 equities research analysts have issued twelve-month price objectives for Eli Lilly and's stock. Their LLY stock forecasts range from $264.00 to $369.00. On average, they anticipate Eli Lilly and's stock price to reach $311.65 in the next year. This suggests that the stock has a possible downside of 4.0%.
View analysts' price targets for Eli Lilly and or view top-rated stocks among Wall Street analysts.

Eli Lilly and's stock was trading at $276.22 on January 1st, 2022. Since then, LLY stock has increased by 17.6% and is now trading at $324.71.
View the best growth stocks for 2022 here.

Eli Lilly and is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Eli Lilly and.

Eli Lilly and Company (NYSE:LLY) announced its quarterly earnings data on Thursday, April, 28th. The company reported $2.62 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.30. The firm earned $7.81 billion during the quarter, compared to the consensus estimate of $7.29 billion. Eli Lilly and had a net margin of 20.90% and a trailing twelve-month return on equity of 97.58%. Eli Lilly and's revenue was up 14.8% compared to the same quarter last year. During the same period last year, the business posted $1.87 EPS.
View Eli Lilly and's earnings history.

Eli Lilly and announced a quarterly dividend on Monday, June 27th. Investors of record on Monday, August 15th will be paid a dividend of $0.98 per share on Friday, September 9th. This represents a $3.92 annualized dividend and a yield of 1.21%. The ex-dividend date is Friday, August 12th.
View Eli Lilly and's dividend history.

Eli Lilly and(NYSE:LLY) pays an annual dividend of $3.92 per share and currently has a dividend yield of 1.21%. Eli Lilly and has been increasing its dividend for 8 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio of Eli Lilly and is 58.07%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Eli Lilly and will have a dividend payout ratio of 41.31% next year. This indicates that Eli Lilly and will be able to sustain or increase its dividend.
View Eli Lilly and's dividend history.

Eli Lilly and declared that its board has initiated a share repurchase program on Monday, May 3rd 2021, which authorizes the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.8% of its shares through open market purchases. Shares buyback programs are usually an indication that the company's leadership believes its shares are undervalued.

Eli Lilly and updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of $8.15-$8.30 for the period, compared to the consensus EPS estimate of $8.19. The company issued revenue guidance of $28.80 billion-$29.30 billion, compared to the consensus revenue estimate of $26.80 billion.

399 employees have rated Eli Lilly and CEO David A. Ricks on Glassdoor.com. David A. Ricks has an approval rating of 86% among Eli Lilly and's employees.

Some companies that are related to Eli Lilly and include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Corcept Therapeutics (CORT), Pacira BioSciences (PCRX), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR) and Omeros (OMER).
View all of LLY's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Eli Lilly and investors own include Johnson & Johnson (JNJ), Pfizer (PFE), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Bristol-Myers Squibb (BMY), Walt Disney (DIS), AT&T (T), Verizon Communications (VZ) and JPMorgan Chase & Co. (JPM).

Eli Lilly and trades on the New York Stock Exchange (NYSE) under the ticker symbol "LLY."

Eli Lilly and's stock is owned by many different retail and institutional investors. Top institutional shareholders include Park National Corp OH (0.00%) and First Financial Bank Trust Division (0.00%). Company insiders that own Eli Lilly and stock include Aarti S Shah, Alfonso G Zulueta, Anne E White, David A Ricks, Donald A Zakrowski, Ilya Yuffa, Jackson P Tai, Joshua L Smiley, Lilly Endowment Inc, Marschall S Runge, Melissa S Barnes, Myles O'neill and Stephen F Fry.
View institutional ownership trends for Eli Lilly and.

LLY stock was sold by a variety of institutional investors in the last quarter, including Park National Corp OH, and First Financial Bank Trust Division. Company insiders that have sold Eli Lilly and company stock in the last two years include Alfonso G Zulueta, Donald A Zakrowski, Ilya Yuffa, Lilly Endowment Inc, and Melissa S Barnes.
View insider buying and selling activity for Eli Lilly and or view top insider-selling stocks.

Shares of LLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of LLY stock can currently be purchased for approximately $324.71.

Eli Lilly and (NYSE:LLY) has a market capitalization of $308.53 billion and generates $28.32 billion in revenue each year. The company earns $5.58 billion in net income (profit) each year or $6.75 on an earnings per share basis.

Eli Lilly and employs 35,000 workers across the globe.

Eli Lilly and was founded in 1876.

Eli Lilly and's mailing address is LILLY CORPORATE CENTER, INDIANAPOLIS IN, 46285. The official website for Eli Lilly and is www.lilly.com. The company can be reached via phone at (317) 276-2000, via email at johnson_philip_l@lilly.com, or via fax at 317-276-4878.